UC San Diego at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
UC San Diego takes part in 2 sessions at ASH 2026 in New Orleans. Its program centres on everyday treatment decisions in multiple myeloma and myelodysplastic syndromes. It covers launching bispecific antibodies for myeloma in community practice and choosing care across the MDS spectrum.
| Organization | ASH 2026 Attendance |
|---|---|
UC San Diego San Diego, CA | |
Public research university in San Diego, California, with a medical school and cancer center. | Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. |
Instantly find 20 buyers from UC San Diego
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction